RAMSEY GOSSELIN: Open Payments
NPI 1083140479 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$974 in 53 payments from 21 companies in 2025. Trend: 2023 $877 · 2024 $1,058 · 2025 $974
Food & beverage: $974
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $195 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $121 |
| Exact Sciences Corporation | 5 | $85 |
| Novo Nordisk Inc | 5 | $80 |
| Lilly USA, LLC | 4 | $75 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| Astellas Pharma US Inc | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Janssen Biotech, Inc. | 1 | $29 |
Products named: VRAYLAR, CAPLYTA, MOUNJARO, Cologuard Collection Kit, GEMTESA, REXULTI, Veozah, Wegovy.
Industry payments across UT — which companies pay providers there.
